Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis
PaperCitations, authors & open-access status
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 347 citations, 2018 year and hybrid oa status.
347
Citations
2018
Year
hybrid
OA Status